Feature | June 02, 2014

Roth Lung Cancer Screening Data Overestimates Costs, Relies on Outdated Definition of a Positive Screening CT

CT lung cancer screening effective, lifesaving and cost-efficient

Lung Cancer CT Screening American College of Radiology

June 2, 2014 —Data regarding screening of individuals at high risk for lung cancer with low-dose computed tomography (CT) presented at the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) overestimates the costs and number of false positive exams due to its reliance on an outdated 4 mm size threshold for defining a positive screen. This differs from the 6-mm threshold used in the American College of Radiology’s Lung-RADS quality assurance tool, which is designed to standardize lung cancer screening CT reporting and management recommendations, reduce confusion in exam interpretation and facilitate outcome monitoring. The National Comprehensive Cancer Network also uses a 6-mm threshold to define a positive screen.

“Published scientific evidence shows that a 6-mm threshold significantly reduces false positive exams and subsequent diagnostic testing. The NLST began enrollment in 2002 and used the 4 mm size threshold to define a positive screen based on scientific knowledge at the time. Since then, our knowledge has increased through multiple published papers from the NLST and iELCAP, and the positive threshold has evolved,” said Ella A. Kazerooni, M.D., chair of the American College of Radiology Lung Cancer Screening Committee. “Use of the 6 mm size threshold reduces positives screens from over 1-in-4 exams to 1-in-10, reducing diagnostic testing and without delay in lung cancer diagnostics. This results in lifesaving screening that is incredibly cost-effective compared to other widespread screening measures.”

Using low-dose computed tomography (CT) scans to screen those at high risk for developing lung cancer has been proven to significantly reduce lung cancer deaths by the largest government sponsored lung cancer screening    in history. The test has also been proven at least as cost-effective, if not more cost effective, than breast and colon cancer screening programs1, and even automobile seatbelts and airbags.2

In December 2013, the United States Preventive Services Task Force (USPSTF) recommended screening of adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years. The Affordable Care Act (ACA) requires private insurers to cover all medical exams or procedures that receive a grade of “B” or higher from the USPSTF without a co-pay. As such, CT lung cancer screening has been deemed an Essential Health Benefit and is covered by many private health insurance plans across this country, while Medicare beneficiaries experience lesser access and increased risk of lung cancer death due to lack of coverage.

The college has launched the ACR Lung Cancer Screening Center program, which provides quality assurance infrastructure to help certify that these lifesaving exams are provided in a safe, effective manner and help facilities consistently ensure the greatest possible lifesaving benefit from these exams. Lung cancer is the nation’s leading cause of cancer death, taking nearly 160,000 lives each year (more than breast, prostate and colon cancer combined). The significant reduction in lung cancer deaths that these exams produce amounts to up to 30,000 people each year that do not have to die from this terrible disease.

Based on available evidence, new guidelines and standards and developing screening infrastructure, the college continues to recommend that the Centers for Medicare & Medicaid Services quickly provide full national coverage for high-risk patients as defined in the USPSTF and provide coverage with evidence for other high-risk patients not included in USPSTF recommendations using data collected through existing registries.

For more information: ww.acr.org


1. The July 2013 Black/Pinsky presentation to the National Institutes of Health (NIH) on CT lung cancer screening cost-effectiveness related that CTLCS is cost effective – particularly compared to breast and colon cancer screening, and has a smaller number needed to screen to save a life. However, the official NLST cost-effectiveness paper has not yet been published.

2. S. Feig. Cost-Effectiveness of Mammography, MRI, and Ultrasonography for Breast Cancer Screening.  Radiol Clin N Am 48 (2010) 879–891 (Table 1 on page 881). Also, data presented at the 2009 Radiological Society of North America meeting showed that mammography is more cost-efficient than seatbelts/airbags. As CT lung cancer screening cost-effectiveness is comparable or better to breast and colorectal cancer screening programs, it is more cost-effective than car seatbelts/airbags.


Related Content

New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Report Finds Identifying Patients for Lung Cancer Screening Not So Simple
News | Lung Cancer | June 18, 2018
New findings in the current issue of The American Journal of Managed Care suggest that getting the right patients to...
Weight-Bearing CT International Study Group Hosts  Scientific Session at AOFAS Conference
News | Computed Tomography (CT) | June 15, 2018
June 15, 2018 —The Weight-Bearing CT International Study Group will host a scientific session on the benefits of weig
Florida Hospital First in State to Adopt NeuroLogica's BodyTom Elite CT
News | Computed Tomography (CT) | June 14, 2018
June 14, 2018 — NeuroLogica, a subsidiary of Samsung Electronics Co.
Riverain Technologies Issued U.S. Patent for Vessel Suppression Technology
News | Computed Tomography (CT) | June 14, 2018
Riverain Technologies announced that the United States Patent and Trademark Office (USPTO) has awarded the company a...
360 Photos | 360 View Photos | June 14, 2018
This is a 360 degree image from the Canon Aquilion 64-slice...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
American Society of Neuroradiology Honors Peter Chang with Cornelius G. Dyke Memorial Award
News | Neuro Imaging | June 13, 2018
Peter Chang, M.D., current neuroradiology fellow at UCSF and recently recruited co-director of the UCI Center for...
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
Women More Likely to Use Other Preventive Health Services Following Mammography
News | Mammography | June 13, 2018
Medicare beneficiaries who undergo breast cancer screening with mammography are more likely than unscreened women to...
Overlay Init